6188-23-4

Basic information

• Product Name: 6-Bromoimidazo[1,2-a]pyridine
• Synonyms: BUTTPARK 154\50-43;6-BROMOIMIDAZO[1,2-A]PYRIDINE;6-BROMO-INIDAZO[1,2-A]-PYRIDINE;6- BROMINE IMIDAZOLYL [ 1,2-A ] PYRIDINE;6-Bromoimidazo[1,2-a]pyri...;6-BroMoiMidazolo[1,2-a]pyridine;IMidazo[1,2-a]pyridine, 6-broMo-;6-BroMo IMidazole[1,2-a]Pyridine
• CAS NO: 6188-23-4
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• EINECS: 1592732-453-0
• Product Categories: blocks;Bromides;Imidazoles;Pyridines;CHIRAL CHEMICALS;Building Blocks;Imidazo[x,x-y]pyridine;Heterocycle-Pyridine series
• Mol File: 6188-23-4.mol

Chemical Properties

• Melting Point: 76-78 °C
• Boiling Point: 165 °C(Press: 1.5 Torr)
• Appearance: /
• Density: 1.69 g/cm³
• Refractive Index: 1.688
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 5.10±0.50(Predicted)
• Water Solubility: slightly soluble in water.
• CAS DataBase Reference: 6-Bromoimidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoimidazo[1,2-a]pyridine(6188-23-4)
• EPA Substance Registry System: 6-Bromoimidazo[1,2-a]pyridine(6188-23-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 6188-23-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Syntheses:
6-Bromoimidazo[1,2-a]pyridine is used as a building block in the synthesis of complex organic molecules. Its unique structure and reactivity make it a valuable component in the development of new organic compounds with potential applications in various fields.
Used in Pharmaceutical Industry:
6-Bromoimidazo[1,2-a]pyridine is used as a pharmaceutical intermediate for the development of new drugs. Its ability to be functionalized and modified allows for the creation of novel drug candidates with potential therapeutic benefits.
Used in Radiolabeled Compounds:
6-Bromoimidazo[1,2-a]pyridine has been used in the synthesis of radiolabeled compounds, such as 1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile hydrochloride monohydrate 6, which was synthesized in 5 steps using [2-14C]cyanoacetamide as the source of the radiolabel. This allows for the study of the compound's biological activity and potential applications in medical research.

InChI:InChI=1/C7H5BrN2/c8-6-1-2-7-9-3-4-10(7)5-6/h1-5H

Synthetic route

2-chloroethanal (107-20-0) + 5-bromo-2-pyridylamine (1072-97-5) → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
Stage #1: 2-chloroethanal; 5-bromo-2-pyridylamine In ethanol; water for 3h; Reflux; Stage #2: With sodium hydrogencarbonate In water	100%
In ethanol; water at 80℃; for 15h;	100%
In ethanol for 6h; Reflux;	98%

5-bromo-2-pyridylamine (1072-97-5) + Bromoacetaldehyde diethyl acetal (2032-35-1) → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
With hydrogen bromide In ethanol; water at 103℃;	97%
With hydrogen bromide In ethanol; water at 100℃; for 8h;	87%
With hydrogen bromide In ethanol; water at 100℃; for 8h;	83%
With hydrogenchloride; sodium hydrogencarbonate 1) H2O, a) r.t., b) 80 deg C, 2) r.t.; Yield given. Multistep reaction;

5-bromo-2-pyridylamine (1072-97-5) + bromoacetaldehyde diethyl acetal → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
With hydrogen bromide In ethanol; water at 100℃; for 8h;	87.2%

5-bromo-2-pyridylamine (1072-97-5) + chloroacetaldehyde dimethyl acetal (97-97-2) → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
Stage #1: 5-bromo-2-pyridylamine; chloroacetaldehyde dimethyl acetal With hydrogenchloride; sodium acetate In ethanol; water for 2.5h; Reflux; Stage #2: With sodium hydrogencarbonate In water pH=Ca. 7;	64.28%
With hydrogenchloride; sodium hydroxide; sodium acetate In water; water ethanol
With hydrogenchloride; sodium hydroxide; sodium acetate In water; water ethanol
With hydrogenchloride; sodium hydroxide; sodium acetate; sodium In water; water ethanol

2-chloroethanal (107-20-0) + 6-bromopyridine-3-amine (13534-97-9) → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
In ethanol; water for 18h; Heating / reflux;

5-bromo-2-pyridylamine (1072-97-5) + chloroacetaldehyde diethyl acetal (621-62-5) → 6-bromoimidazo[1,2-a]pyridine (6188-23-4)

Conditions	Yield
Stage #1: chloroacetaldehyde diethyl acetal With hydrogenchloride In water at 90℃; for 0.166667h; Stage #2: 5-bromo-2-pyridylamine With sodium acetate In ethanol; water for 0.333333h; Reflux;

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + methylamine (74-89-5) + molybdenum hexacarbonyl (13939-06-5, 199620-15-0) → N-methylimidazo[1,2-a]pyridine-6-carboxamide

Conditions	Yield
With palladium [2'-(amino-κN)[1,1'-biphenyl]-2-yl-κC][[5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphine-κP](methanesulfonato-κO); 1,8-diazabicyclo[5.4.0]undec-7-ene; triethylamine In tetrahydrofuran; 1,4-dioxane at 85℃; Inert atmosphere; Sealed tube;	100%

phosphonic acid diethyl ester (762-04-9) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → diethyl imidazo[1,2-a]pyridin-6-ylphosphonate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); triethylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In toluene at 110℃; for 2h; Inert atmosphere;	100%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromo-3-nitro-imidazo[1,2-a]pyridine (64064-71-7)

Conditions	Yield
With sulfuric acid; nitric acid In water at 20℃; for 0.25h;	99%
With nitric acid In sulfuric acid
With nitric acid In sulfuric acid
With nitric acid In sulfuric acid

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + N,N-dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline → C15H15N3

Conditions	Yield
With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); dicyclohexyl(2',4',6'-triisopropyl-[1,1':3',1''-terphenyl]-2-yl)phosphane In 1,4-dioxane; water at 100℃;	99%

ethyl (3-methylphenyl)phosphinate (1096142-78-7) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → ethyl imidazo[1,2-a]pyridin-6-yl(m-tolyl)phosphinate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); triethylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In toluene at 110℃; for 2h; Inert atmosphere;	99%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromoimidazo[1,2-a]pyridine-3-sulfonic acid

Conditions	Yield
With chlorosulfonic acid In chloroform for 24h; Reflux;	98%
With chlorosulfonic acid In chloroform for 16h; Reflux;	85%
With chlorosulfonic acid In chloroform for 24h; Reflux;

6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromo-3-iodoimidazo[1,2-a]pyridine (474706-74-6)

Conditions	Yield
With N-iodo-succinimide In acetonitrile at 20℃; for 1h;	96%
With N-iodo-succinimide In acetonitrile at 20℃; for 12h; Inert atmosphere;	85%
With N-iodo-succinimide In acetonitrile for 16.0833h;	77%

dimethyl amine (124-40-3) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) + molybdenum hexacarbonyl (13939-06-5, 199620-15-0) → N,N-dimethylimidazo[1,2-a]pyridine-6-carboxamide

Conditions	Yield
With palladium [2'-(amino-κN)[1,1'-biphenyl]-2-yl-κC][[5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphine-κP](methanesulfonato-κO); 1,8-diazabicyclo[5.4.0]undec-7-ene; triethylamine In tetrahydrofuran; 1,4-dioxane at 85℃; Inert atmosphere; Sealed tube;	96%

N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide (1083326-73-1) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 2,4-difluoro-N-(5-(imidazo[1,2-a]pyridin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide (1609565-45-8)

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In 1,4-dioxane; water at 110℃; for 3h; Suzuki Coupling; Inert atmosphere;	95%
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In 1,4-dioxane; water at 110℃; for 3h; Suzuki Coupling; Inert atmosphere;	95%
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate In 1,2-dimethoxyethane; water at 70℃; for 6h; Inert atmosphere;

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + (2-methylpyridin-3-yl)boronic acid (899436-71-6) → 6-(2-methylpyridin-3-yl)imidazo[1,2-a]pyridine (1611001-25-2)

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In N,N-dimethyl-formamide at 120℃; for 2h; Inert atmosphere;	95%

diisopropyl hydrogenphosphonate (1809-20-7) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → diisopropyl imidazo[1,2-a]pyridin-6-ylphosphonate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); triethylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In toluene at 110℃; for 2h; Inert atmosphere;	94%

ethyl [3-(trifluoromethyl)phenyl]phosphinate (1335150-96-3) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → ethyl imidazo[1,2-a]pyridin-6-yl(3-(trifluoromethyl)phenyl)phosphinate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); triethylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In toluene at 110℃; for 4h; Inert atmosphere;	93%

5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-trifluoromethyl-pyridin-2-ylamine (947249-01-6) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 5-(imidazo[1,2-a]pyridin-6-yl)-3-(trifluoromethyl)pyridin-2-amine (1611001-27-4)

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate In N,N-dimethyl-formamide at 120℃; for 2h; Inert atmosphere;	92.12%

2-((difluoromethyl)thio)isoindoline-1,3-dione + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromo-3-((difluoromethyl)thio)imidazo[1,2-a]pyridine

Conditions	Yield
With sodium chloride In N,N-dimethyl-formamide at 80℃; for 16h; Schlenk technique; Inert atmosphere;	92%

isobutyraldehyde (78-84-2) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromo-3-(2-methyl-propenyl)-imidazo[1,2-a]pyridine

Conditions	Yield
With acetic acid at 130℃; for 10h;	91%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + Diphenylphosphine oxide (4559-70-0) → imidazo[1,2-a]pyridin-6-yldiphenylphosphine oxide

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); triethylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In toluene at 110℃; for 5h; Inert atmosphere;	91%

benzaldehyde (100-52-7) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → C21H14Br2N4

Conditions	Yield
With sodium acetate; acetic acid for 24h; Heating;	90%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + pyrimidine 5-boronic acid (109299-78-7) → 6-(pyrimidin-5-yl)imidazo[1,2-a]pyridine (1611001-15-0)

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate In N,N-dimethyl-formamide at 120℃; for 2h; Inert atmosphere;	90%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + cyclopropylboronic acid (411235-57-9) → 6-cyclopropylimidazo[1,2-a]pyridine

Conditions	Yield
With potassium phosphate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 In 1,4-dioxane at 100℃;	90%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + (6-methylpyridin-3-yl)boronic acid (659742-21-9) → 6-(6-methylpyridin-3-yl)imidazo[1,2-a]pyridine (1611000-95-3)

Conditions	Yield
With bis-triphenylphosphine-palladium(II) chloride; potassium carbonate In water; N,N-dimethyl-formamide at 120℃; for 2h; Inert atmosphere;	89%

2-methyl-3-buten-2-ol (115-18-4) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → (E)-4-(imidazo[1,2-a]pyridin-6-yl)-2-methylbut-3-en-2-ol

Conditions	Yield
With dicyclohexyl(2',4',6'-triisopropyl-[1,1':3',1''-terphenyl]-2-yl)phosphane; palladium diacetate; sodium hydrogencarbonate In N,N-dimethyl-formamide at 120℃; for 8h; Sealed tube; Inert atmosphere; Glovebox; Schlenk technique;	89%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + 1-dodecylthiol (112-55-0) → C19H29BrN2S

Conditions	Yield
With copper(l) iodide; oxygen In dimethyl sulfoxide at 100℃; regioselective reaction;	89%

pyrazole-4-boronic acid pinacol ester (269410-08-4) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine (1205744-45-1)

Conditions	Yield
With sodium carbonate; bis(dibenzylideneacetone)-palladium(0); tricyclohexylphosphine In water; N,N-dimethyl-formamide at 130℃; for 0.5h; Microwave irradiation; Inert atmosphere;	89%

4-pyridylboronic acid (1692-15-5) + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-(4-pyridinyl)imidazo[1,2-a]pyridine

Conditions	Yield
With sodium carbonate; bis(dibenzylideneacetone)-palladium(0); tricyclohexylphosphine In water; N,N-dimethyl-formamide at 130℃; for 0.5h; Microwave irradiation; Inert atmosphere;	89%

lithium 2,4-dimethoxypyrimidine-5-sulfinate + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-(2,4-dimethoxypyrimidin-5-yl)imidazo[1,2-a]pyridine

Conditions	Yield
Stage #1: lithium 2,4-dimethoxypyrimidine-5-sulfinate With potassium carbonate In 1,4-dioxane for 0.25h; Sealed tube; Inert atmosphere; Stage #2: 6-bromoimidazo[1,2-a]pyridine With palladium diacetate; tricyclohexylphosphine In 1,4-dioxane at 140℃; for 24h; Sealed tube; Inert atmosphere; Sonication;	89%

N-(benzenesulfonyl)-N-[(trifluoromethyl)sulfanyl]benzenesulfonamide + 6-bromoimidazo[1,2-a]pyridine (6188-23-4) → 6-bromo-3-(trifluoromethylthio)imidazo[1,2-a]pyridine

Conditions	Yield
In N,N-dimethyl-formamide at 80℃; for 1h; Schlenk technique; Inert atmosphere;	88%

6-bromoimidazo[1,2-a]pyridine (6188-23-4) + 2-methoxy-pyridine-5-boronic acid (163105-89-3) → 6-(6-methoxypyridin-3-yl)imidazo[1,2-a]pyridine (1611001-50-3)

Conditions	Yield
With bis-triphenylphosphine-palladium(II) chloride; potassium carbonate In N,N-dimethyl-formamide at 120℃; for 2h; Inert atmosphere;	87.71%

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 
• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 13534-97-9 6-bromopyridine-3-amine 
• 621-62-5 chloroacetaldehyde diethyl acetal 

Downstream Products

• 328062-45-9 6-phenylimidazo[1,2-a]pyridine 
• 106730-54-5 olprinone 
• 474706-74-6 6-bromo-3-iodoimidazo[1,2-a]pyridine 
• 474706-61-1 6-[3-(4-fluorophenyl)-1-trityl-1H-4-pyrazolyl]imidazo[1,2-a]-pyridine 
• 116355-16-9 6-imidazo<1,2-a>pyridinecarboxaldehyde 
• 64064-71-7 6-bromo-3-nitro-imidazo[1,2-a]pyridine 
• 1065074-14-7 3-bromo-6-bromo-imidazo[1,2-a]pyridine 
• 1313488-90-2 N-(2-chloro-5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1426845-61-5 2-(4-fluorophenyl)-5-(imidazo[1,2-a]pyridin-6-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1426845-60-4 5-(3-bromo-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1426845-31-9 2-(4-fluorophenyl)-5-(3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1202701-37-8 (S)-(N-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-6-yl)phenyl)-2-oxo-5-oxazolidinyl)methylacetamide 
• 1202703-33-0 (R)-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-6-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one 
• 1609565-46-9 2,4-difluoro-N-(5-(3-iodoimidazo[1,2-a]pyridin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

FMS-like tyrosine kinase 3 (FLT3) with an internal tandem duplication (ITD) mutation has been validated as a driver lesion and a therapeutic target for acute myeloid leukemia (AML). Currently, several potent small-molecule FLT3 kinase inhibitors are being evaluated or have completed evaluation in clinical trials. However, many of these inhibitors are challenged by the secondary mutations on kinase domain, especially the point mutations at the activation loop (D835) and gatekeeper residue (F691). To overcome the resistance challenge, we identified a novel series of imidazo[1,2-a]pyridine-thiophene derivatives from a NIMA-related kinase 2 (NEK2) kinase inhibitor CMP3a, which retained inhibitory activities on FTL3-ITDD835V and FLT3-ITDF691L. Through this study, we identified the imidazo[1,2-a]pyridine-thiophene derivatives as type-I inhibitors of FLT3. Moreover, we observed compound 5o as an inhibitor displaying equal anti-proliferative activities against FLT3-ITD, FTL3-ITDD835Y and FLT3-ITDF691L driven acute myeloid leukemia (AML) cell lines. Meanwhile, the apoptotic effects of compound supported its mechanism of anti-proliferative action. These results indicate that the imidazo[1,2-a]pyridine-thiophene scaffold is promising for targeting acquired resistance caused by FLT3 secondary mutations and compound 5o is an interesting lead in this direction.

Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors

Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively. MNKs modulate the translation of mRNA involved in tumor-associated signaling pathways. Consequently, selective inhibitors of MNK1/2 could reduce the level of phosphorylated eIF4E. Series of imidazopyrazines, imidazopyridazines and imidazopyridines derivatives were synthesized and evaluated as MNK1/2 inhibitors. Several compounds exhibited great inhibitory activity against MNK1/2 and selected compounds showed moderate to excellent anti-proliferative potency against diffuse large B-cell lymphoma (DLBCL) cell lines. In particular, compound II-5 (MNK1 IC50 = 2.3 nM; MNK2 IC50 = 3.4 nM) exhibited excellent enzymatic inhibitory potency and proved to be the most potent compound against TMD-8 and DOHH-2 cell lines with IC50 value of 0.3896 μM and 0.4092 μM respectively. These results demonstrated that compound II-5 could be considered as a potential MNK1/2 inhibitor for further investigation.

INHIBITORS OF LIN28 AND METHODS OF USE THEREOF

The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cancers.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2- a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.

Imidazopyridine MNK1/MNK2 kinase inhibitor as well as preparation method and application thereof

The invention provides an imidazopyridine MNK1/MNK2 kinase inhibitor as well as a preparation method and application thereof, and particularly provides a compound as shown in a formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The compound provided by the invention can be used for preparing a pharmaceutical composition for treating diseases or symptoms related to MNK activity or expression quantity.

Imidazopyridine MNK1/MNK2 kinase inhibitor, and preparation method and application thereof

The invention provides an imidazopyridine MNK1/MNK2 kinase inhibitor, and a preparation method and application thereof. The invention particularly provides a compound as shown in a formula (I) which is described in the specification, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The compound provided by the invention can be used for preparing a pharmaceutical composition for treating diseases or symptoms related to MNK activity or expression quantity.

Imidazo [1, 2 - a] pyridine derivatives and preparation method and application thereof (by machine translation)

The invention discloses 3 -phenyl imidazo [1, 2 - a] pyridine derivatives represented by a formula (I) or 3 - (thiophene -2 substituted) imidazo [1, 2 - a] pyridine derivatives and a preparation method, and also discloses application. of the 3 -phenyimidazo [1, 2 - a] pyridine derivatives or 3 - (thiophene -2 substituted) imidazo [1, 2 - a] pyridine derivatives as a class of novel structural novel small molecule inhibitors, and the like. (by machine translation)

Aromatic heterocyclic compound serving as PI3K/mTOR kinase regulator and preparation method and application of aromatic heterocyclic compound

The invention discloses 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-a]pyridines shown as a formula (I) or 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-b]pyridazine derivatives or pharmaceutically acceptable salts thereof and a preparation method. The invention also discloses application of 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-a]pyridines or6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-b]pyridazine derivatives or pharmaceutically acceptable salts thereof to preparation of medicines for resisting tumors, treating cerebral ischemia and treating diabetes mellitus as a PI3K/mTOR inhibitor.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.